Related Experiment Videos

Juvenile idiopathic arthritis: an update on clinical and therapeutic approaches

Laura Quarta1, Addolorata Corrado, Nadia Melillo

  • 1Clinica Reumatologica M. Carrozzo, Universiti degli Studi di Foggia.

Annali Italiani Di Medicina Interna : Organo Ufficiale Della Societa Italiana Di Medicina Interna
|April 14, 2006
PubMed

Insights

Juvenile idiopathic arthritis (JIA) is a complex autoimmune condition affecting children, leading to growth issues and bone problems. New biologic therapies targeting tumor necrosis factor-alpha show promise for managing JIA.

Area of Science:

  • Pediatric Rheumatology
  • Immunology
  • Autoimmune Diseases

Background:

  • Juvenile idiopathic arthritis (JIA) is a diverse autoimmune disorder in children under 16.
  • It can lead to significant complications like growth retardation, osteopenia, and fractures.
  • Diagnosis of JIA is often one of exclusion due to its varied presentation.

Purpose of the Study:

  • To review the challenges in diagnosing and treating JIA.
  • To highlight the impact of JIA on skeletal development.
  • To discuss emerging therapeutic strategies for JIA.

Main Methods:

  • Literature review of JIA pathogenesis and treatment.
  • Analysis of current therapeutic approaches, including NSAIDs, DMARDs, and glucocorticoids.
  • Examination of novel biologic therapies targeting cytokines.

Main Results:

  • Standard treatments include NSAIDs, methotrexate, and judicious use of glucocorticoids.
  • Glucocorticoids pose risks of growth inhibition and osteoporosis.
  • Tumor necrosis factor-alpha plays a key role in JIA pathogenesis.

Conclusions:

  • JIA requires careful management due to potential long-term skeletal complications.
  • Biologic agents like infliximab and etanercept offer new avenues for JIA treatment by targeting TNF-alpha.
  • Further research into targeted therapies is crucial for improving JIA outcomes.

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Inflammatory Bowel Disease IV: Clinical Manifestations01:20

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...